1991
DOI: 10.4049/jimmunol.146.3.1020
|View full text |Cite
|
Sign up to set email alerts
|

Monoclonal, but not polyclonal, antibodies protect against Plasmodium yoelii sporozoites.

Abstract: One of the primary strategies for malaria vaccine development has been to design subunit vaccines that induce protective levels of antibodies against the circumsporozoite (CS) protein of malaria sporozoites. In the Plasmodium yoelii mouse model system such vaccines have been uniformly unsuccessful in protecting against sporozoite-induced malaria. To demonstrate that antibodies to P. yoelii CS protein could provide protection we established a passive transfer model. Passive transfer of Navy yoelii sporozoite 1 … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
10
0

Year Published

1993
1993
2018
2018

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 110 publications
(10 citation statements)
references
References 0 publications
0
10
0
Order By: Relevance
“…The circumsporozoite protein (CSP) is the major surface protein of malaria sporozoites (SPZs), the motile and invasive parasite stage inoculated in the host skin by infected mosquitoes. Antibodies against the central CSP repeats of different plasmodial species are known to block SPZ infectivity [1][2][3][4][5] , but the precise mechanism by which these effectors operate is not completely understood. Here, using a rodent Plasmodium yoelii (Py) The CSP forms a dense-coat on the SPZ surface, being essential for the development of nascent SPZs in the mosquito midgut 10 .…”
mentioning
confidence: 99%
See 3 more Smart Citations
“…The circumsporozoite protein (CSP) is the major surface protein of malaria sporozoites (SPZs), the motile and invasive parasite stage inoculated in the host skin by infected mosquitoes. Antibodies against the central CSP repeats of different plasmodial species are known to block SPZ infectivity [1][2][3][4][5] , but the precise mechanism by which these effectors operate is not completely understood. Here, using a rodent Plasmodium yoelii (Py) The CSP forms a dense-coat on the SPZ surface, being essential for the development of nascent SPZs in the mosquito midgut 10 .…”
mentioning
confidence: 99%
“…The central repetitive domain and the CT region constitute the basis for the most advanced malaria vaccine candidate, RTS,S/AS01, which partially protects humans against malaria 16 , presumably via high levels of anti-PfCSP repeats antibodies 17 . Indeed, mAbs targeting the CSP central repeats are known to immobilize SPZs and inhibit their infectivity both in vitro [18][19][20] and in vivo [1][2][3][4][5]7 . Accordingly, human, monkey and rodent-infecting SPZs lose their in vivo infectivity following pre-incubation with anti-CSP mAbs [1][2][3] or when intravenously (iv) inoculated into passively immunized hosts 4,5,21 .…”
mentioning
confidence: 99%
See 2 more Smart Citations
“…It is clear that antibodies directed against the repeat region of CSP can provide protection against malaria. In rodent and nonhuman primate models, passive transfer of antibodies directed against the repeat region of P. berghei, P. yoelii, and P. vivax CSPs can protect from experimental challenge [56,57,58,59]. In this study, CSP-specific antibody responses appeared to correlate with protection as regimens that induced the highest levels of protection (heterologous Ad and DNA prime-Ad boost) were associated with higher CSP-specific antibody responses relative to regimens showing poor protective responses (Ad5 vector alone or the homologous Ad5 vector prime-boost regimen).…”
Section: Discussionmentioning
confidence: 99%